9O2D

Heparanase P6 in complex with fragment J74 (L-norepinephrine)

9O2D の概要

• エントリーDOI: 10.2210/pdb9o2d/pdb
• 分子名称: Heparanase 50 kDa subunit, Heparanase 8 kDa subunit, DI(HYDROXYETHYL)ETHER, ... (6 entities in total)
• 機能のキーワード: heparanase, small molecule, cancer, complex, therapeutics, hydrolase
• 由来する生物種: Homo sapiens (human); 詳細
• タンパク質・核酸の鎖数: 2
• 化学式量合計: 52121.56

構造登録者

Davies, L.J.,Frkic, R.L.,Jackson, C.J. (登録日: 2025-04-03, 公開日: 2026-02-11, 最終更新日: 2026-03-04)

主引用文献

Davies, L.J.,Whitefield, C.,Kim, H.,Nitsche, C.,Jackson, C.J.,Frkic, R.L.
Fragment Screening and Structure-Guided Development of Heparanase Inhibitors Reveal Orthosteric and Allosteric Inhibition.
Acs Med.Chem.Lett., 17:383-390, 2026

PubMed Abstract: Heparanase is the sole enzyme responsible for breaking down heparan sulfate within the extracellular matrix, and its overexpression is linked to human diseases. Despite heparanase being a promising drug target, most efforts have focused on substrate mimetics, which have failed clinical trials, highlighting the need for new inhibitor scaffolds. Here, we employed fragment-based drug design to explore a novel chemical space to develop small molecule inhibitors of heparanase. We used a crystallographic and computational approach to identify 31 fragments that bind heparanase; five of these inhibited heparanase in the micromolar range. One of these fragments underwent two cycles of fragment growing, which resulted in a compound with a 7-fold increased potency compared to the initial hit. The results from our fragment screen unveil untapped chemical space for heparanase inhibition, paving the way for the development of potent drug leads with the potential to transform the treatment of heparanase-related diseases.

PubMed: 41704381
DOI: 10.1021/acsmedchemlett.5c00587

実験手法

X-RAY DIFFRACTION (2.3 Å)